Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA…
Founded in 1974, the Association of Black Cardiologists, Inc., (ABC) is a nonprofit organization with an international membership of 2,500 health professionals, lay…
Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and…
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company's singular mission is…
Nephros is a commercial stage medical device company that develops and sells high-performance liquid purification filters. Nephros filters capture contaminants as…
BSIM's mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and…
Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally…
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the…
Amyloidosis is a rare disease that manifests itself when amyloid protein deposits accumulate in the body's organs and tissues, ultimately causing organ failure if…